• Sunday, December 18, 2022 @ 12:00 am

US and EU approval of vamorolone with peak sales of CHF 650+ mn in DMD alone will be transformational for Santhera. The equity upside should be a multiple of the likely share dilution to raise an estimated CHF 40 mn to build up a US and EU specialist sales force to commercialize vamorolone and maximize its long-term profitability.

Key catalysts include:

1. Vamorolone FDA “acceptance of filing” (January 2023)
2. Vamorolone US approval in DMD (Q2 2023)
3. Vamorolone EU approval in DMD (Q4 2023)

Read full Santhera Valuation Report

You may also be interested in